Alvogen launches new cancer generics in Romania; Mylan debuts Uroxatral copy in USA

US copy drugmaker Alvogen said last Friday that its subsidiary, Alvogen Romania, has launched generic versions of three oncology products in that market. The drugs to debut in Romania are:

•  exemestane is an oral aromatase inhibitor, for early breast cancer in postmenopausal women. It is the generic equivalent of Pfizer’s Aromasin, and available in 25mg tablets;
• irinotecan (Irinotecan hydrochloride trihydrate), the generic equivalent of Pfizer’s Campto and is a cytostatic, a treatment for advanced colorectal cancer. The product is available in a 20mg/ml amber tubular glass vial; and
• letrozole, an oral non-steroidal aromatase inhibitor for the treatment of hormonally-responsive breast cancer after surgery in postmenopausal women. It is the generic equivalent of Novartis’ Femara, available in a carton box containing 30 film-coated tablets.

All three products are fully compensated by Romania’s National Health Insurance Fund and available in the Alvogen Romania warehouse for immediate shipment to hospitals and pharmacies, the company noted.